文献速递临床试验与 GCP真实世界研究与卫生经济

在乌干达五家医院中,临床稳定前开始袋鼠式母亲护理与标准护理对新生儿的效果比较(OMWaNA):平行组、个体随机对照试验及经济学评价

Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation.
PubMed 文献 · Lancet · 2024-05-13

该平行组个体随机对照试验在乌干达五家医院纳入体重700-2000g、日龄小于48小时且无危及生命临床不稳定的新生儿,1:1随机分为稳定前开始袋鼠式母亲护理组与标准护理组,主要结局为7日龄全因新生儿死亡。结果显示干预未降低早期新生儿死亡率(校正RR 0.97,95%CI 0.74-1.28;p=0.85),但从社会视角和提供者视角均具成本效果。

要点

  • 稳定前开始袋鼠式母亲护理未降低7日龄全因新生儿死亡(校正RR 0.97,95%CI 0.74-1.28;p=0.85)。
  • 28日龄死亡干预组11.3% vs 对照组12.8%(RR 0.88,95%CI 0.71-1.09;p=0.23)。
  • 干预从提供者视角有97%概率、社会视角有84%概率比标准护理更具成本效果。

核心结论

  • 临床稳定前开始袋鼠式母亲护理未降低早期新生儿死亡率,但从社会视角和提供者视角均具成本效果。
  • 作者认为需要额外投资新生儿护理以增加影响,尤其在撒哈拉以南非洲。

研究设计与样本

  • 平行组、个体随机对照试验及经济学评价,在乌干达五家医院开展。
  • 纳入日龄小于48小时、体重700-2000g、无危及生命临床不稳定的单胎或双胎新生儿。
  • 1:1随机分为稳定前开始袋鼠式母亲护理组(干预组)或标准护理组(对照组),按出生体重和招募地点分层,采用计算机生成随机分配序列和可变区组。
  • 主要结局为7日龄全因新生儿死亡,按意向性治疗分析;经济学评价从分解的社会视角评估增量成本和成本效果。
  • 试验注册号ClinicalTrials.gov,NCT02811432。

主要发现

  • 2019年10月9日至2022年7月31日共随机分配2221名新生儿:干预组1110名(50.0%),对照组1111名(50.0%)。
  • 从随机化至7日龄,干预组1083名中81名(7.5%)死亡,对照组1102名中83名(7.5%)死亡(校正相对危险度[RR] 0.97 [95%CI 0.74-1.28];p=0.85)。
  • 从随机化至28日龄,干预组1051名中119名(11.3%)死亡,对照组1049名中134名(12.8%)死亡(RR 0.88 [95%CI 0.71-1.09];p=0.23)。
  • 即使决策者不对避免新生儿死亡赋予价值,干预从提供者视角有97%概率、从社会视角有84%概率比标准护理更具成本效果。

临床怎么用

  • 作者认为临床稳定前开始袋鼠式母亲护理未降低早期新生儿死亡率,但从社会视角和提供者视角均具成本效果。
  • 作者认为需要额外投资新生儿护理以增加影响,尤其在撒哈拉以南非洲。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preterm birth is the leading cause of death in children younger than 5 years worldwide. WHO recommends kangaroo mother care (KMC); however, its effects on mortality in sub-Saharan Africa and its relative costs remain unclear. We aimed to compare the effectiveness, safety, costs, and cost-effectiveness of KMC initiated before clinical stabilisation versus standard care in neonates weighing up to 2000 g. METHODS: We conducted a parallel-group, individually randomised controlled trial in five hospitals across Uganda. Singleton or twin neonates aged younger than 48 h weighing 700-2000 g without life-threatening clinical instability were eligible for inclusion. We randomly assigned (1:1) neonates to either KMC initiated before stabilisation (intervention group) or standard care (control group) via a computer-generated random allocation sequence with permuted blocks of varying sizes, stratified by birthweight and recruitment site. Parents, caregivers, and health-care workers were unmasked to treatment allocation; however, the independent statistician who conducted the analyses was masked. After randomisation, neonates in the intervention group were placed prone and skin-to-skin on the caregiver's chest, secured with a KMC wrap. Neonates in the control group were cared for in an incubator or radiant heater, as per hospital practice; KMC was not initiated until stability criteria were met. The primary outcome was all-cause neonatal mortality at 7 days, analysed by intention to treat. The economic evaluation assessed incremental costs and cost-effectiveness from a disaggregated societal perspective. This trial is registered with ClinicalTrials.gov, NCT02811432. FINDINGS: Between Oct 9, 2019, and July 31, 2022, 2221 neonates were randomly assigned: 1110 (50·0%) neonates to the intervention group and 1111 (50·0%) neonates to the control group. From randomisation to age 7 days, 81 (7·5%) of 1083 neonates in the intervention group and 83 (7·5%) of 1102 neonates in the control group died (adjusted relative risk [RR] 0·97 [95% CI 0·74-1·28]; p=0·85). From randomisation to 28 days, 119 (11·3%) of 1051 neonates in the intervention group and 134 (12·8%) of 1049 neonates in the control group died (RR 0·88 [0·71-1·09]; p=0·23). Even if policy makers place no value on averting neonatal deaths, the intervention would have 97% probability from the provider perspective and 84% probability from the societal perspective of being more cost-effective than standard care. INTERPRETATION: KMC initiated before stabilisation did not reduce early neonatal mortality; however, it was cost-effective from the societal and provider perspectives compared with standard care. Additional investment in neonatal care is needed for increased impact, particularly in sub-Saharan Africa. FUNDING: Joint Global Health Trials scheme of the Department of Health and Social Care, Foreign, Commonwealth and Development Office, UKRI Medical Research Council, and Wellcome Trust; Eunice Kennedy Shriver National Institute of Child Health and Human Development.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Tumukunde V, Medvedev MM, Tann CJ, et al. Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation. Lancet. 2024. PMID: 38754454. doi:10.1016/S0140-6736(24)00064-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。